All In Biotech

Free tool

FAERS Monitor: Zilretta

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208845 or its brand name (Zilretta, Triamcinolone Acetonide). Reports on generic versions are filed under their own applications.

Reports

864

Serious

179

21% of reports

Hospitalization

85

Death reported

10

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • recalled product administered226
  • arthralgia126
  • drug ineffective78
  • no adverse event78
  • joint swelling47
  • therapeutic response shortened44
  • pain41
  • blood glucose increased35
  • headache29
  • arthritis bacterial28
  • off label use27
  • blood pressure increased22
  • gait disturbance22
  • joint effusion20
  • muscle spasms18

Reports by year received

View as table
YearReports
201836
2019122
202095
202185
202277
202357
2024310
202567
202615

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,295 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
recalled product administeredSignal226590.8527.2129,406
arthritis bacterialSignal28167.2116.04,432
joint effusionSignal2070.845.91,304
therapeutic response shortenedSignal4432.324.21,305
no adverse eventSignal7810.58.5665
joint swellingSignal479.57.2350
arthralgiaSignal1267.46.3702
blood glucose increasedSignal354.53.393
blood pressure increasedSignal223.52.337
gait disturbanceSignal222.81.924
muscle spasmsSignal182.41.513
pain411.61.210
drug ineffective781.41.211
headache291.10.80
off label use270.80.52

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.